Drug rechallenge and treatment beyond progression--implications for drug resistance.
Ontology highlight
ABSTRACT: The established dogma in oncology for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant. Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated. Over the past few decades, clinical evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents. There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy. Additional, albeit limited, eviden
SUBMITTER: Kuczynski EA
PROVIDER: S-EPMC4540602 | biostudies-literature | 2013 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA